January 1, 1995Leukemia & lymphoma/Leukemia and lymphoma
Phase III Comparative Trial Uisng CHOP vs CIOP in the Treatment of Advanced Intermediate-Grade Non-Hodgkin's Lymphoma
Key result
CIOP matches CHOP complete response rates while reducing median LVEF drop by ~42%.
- n=115
Why the study?
The CHOP regimen is the standard first-line treatment for advanced intermediate-grade non-Hodgkin's lymphoma, but idarubicin's efficacy and safety compared to doxorubicin needed evaluation.
Does the CIOP regimen reduce cardiotoxicity while maintaining equivalent efficacy compared to the CHOP regimen in patients with advanced intermediate-grade non-Hodgkin's lymphoma?
Population
115 previously untreated patients with stage II to IV intermediate-grade non-Hodgkin's lymphoma
Comparison
CIOP regimen (idarubicin) vs CHOP regimen (doxorubicin)
Design
Phase III comparative randomized trial
Follow-up
30 months (median 20 months)
Authors
Discussion
Loading...
Member takes
Implication
Supports CIOP as CHOP alternative with equivalent efficacy and less LVEF decline; extends randomized data on anthracycline selection in intermediate-grade NHL.
Study Design
Type
RCT (n=115)
Structured PICO
Does the CIOP regimen reduce cardiotoxicity while maintaining equivalent efficacy compared to the CHOP regimen in patients with advanced intermediate-grade non-Hodgkin's lymphoma?
P
Population
115 previously untreated patients with stage II to IV intermediate-grade non-Hodgkin's lymphoma, followed for a median of 20 months.
I
Intervention
CIOP regimen (cyclophosphamide, idarubicin, vincristine, and dexamethasone)
C
Comparator
CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and dexamethasone)
O
Outcome
Efficacy (response rates, survival) and safety (clinical toxicity, cardiac adverse events, LVEF drop)safety
Main Result
Absolute Event Rate: 59% vs 63%
Substituting idarubicin for doxorubicin in the treatment of advanced non-Hodgkin's lymphoma maintains therapeutic efficacy while significantly reducing cardiotoxicity.
Cite This Study
Zinzani et al. (1995) conducted an RCT in Advanced intermediate-grade non-Hodgkin's lymphoma (n=115). CIOP regimen (idarubicin) vs. CHOP regimen (doxorubicin) was evaluated on Complete response. The idarubicin-containing CIOP regimen yielded equivalent complete response rates to CHOP (59% vs 63%) but with a significantly smaller median drop in LVEF (4.8% vs 8.3%, P=0.0001).